乳腺癌免疫检查点抑制剂疗效预测相关指标的研究进展

Biomarkers for Efficacy of Immune Checkpoint Inhibitors in Breast cancer

免疫治疗是目前治疗三阴性乳腺癌(triple-negative breast cancer,TNBC)及乳腺癌晚期患者的新方法。然而,针对程序性死亡受体1(programmed cell death protein-1,PD-1)/程序性死亡受体-配体1(programmed cell death-ligand 1,PD-L1)的单抗在乳腺癌患者中的总体疗效并不理想,因此寻找并通过有效的生物标志物筛选乳腺癌患者中的获益人群是乳腺癌免疫治疗得到突破的关键。目前,包括PD-L1和肿瘤突变负荷(tumor mutational burden,TMB)等多个标志物已获批用于肺癌和黑素瘤等免疫治疗的疗效预测。本文总结了与乳腺癌免疫治疗生物标志物相关的研究文献,重点关注免疫检查点抑制剂的疗效和预后生物标志物在临床应用中的研究进展,阐述了可能用于指导乳腺癌临床决策及治疗方案的潜在生物标志物。

Immune Checkpoint Inhibitors is a new treatment for triple-negative and advanced breast cancer patients.However,the overall response of programmed cell death protein-1(PD-L1)/PD-ligand 1(PD-1)monoclonal antibody in breast cancer patients is not satisfied.Finding and using effective biomarkers to screen the patients who can benefit from treatment is the key to achieve a breakthrough in breast cancer immunotherapy.At present,a number of biomarkers,including PD-L1,tumor mutational burden(TMB)and so on,have been proved to predict the efficacy of Inhibitors such as lung cancer and melanoma.This paper summarizes the researches about the biomarkers of immunotherapy related to breast cancer,focusing on the efficacy of immune checkpoint inhibitors and the clinical application of prognostic biomarkers.This paper describes the potential biomarkers of breast cancer that may be used to guide clinical decision-making and treatment.